Global Chronic Kidney Disease (CKD) Market, By Product Type (Diagnosis, Treatment), Route of Administration (Oral, Intravenous, Subcutaneous), End Users (Hospitals, Diagnostic Laboratories, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Industry Trends and Forecast to 2030.
Chronic Kidney Disease (CKD) Market Analysis and Size
Chronic Kidney Disease (CKD) is a long-term condition in which the kidneys gradually lose function. The kidneys play a crucial role in filtering waste products, excess fluids, and toxins from the blood while also regulating blood pressure, electrolyte balance, and red blood cell production. CKD typically progresses slowly and may lead to kidney failure if left untreated. Diabetes, glomerulonephritis, polycystic kidney disease, and high blood pressure are the causes of CKD. If CKD is suspected, a healthcare provider may order several tests, including blood tests to measure kidney function (creatinine and blood urea nitrogen levels), urine tests, imaging studies (ultrasound and CT scan), and kidney biopsy in some cases.
Data Bridge Market Research analyses that the Chronic Kidney Disease (CKD) market which was USD 13,220.00 million in 2022, would rocket up to USD 18,800.17 million by 2030, and is expected to undergo a CAGR of 4.5% during the forecast period. This indicates that the market value. Diagnosis dominates the product type segment of the Chronic Kidney Disease (CKD) market owing to the increasing prevalence of CKD. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chronic Kidney Disease (CKD) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Diagnosis, Treatment), Route of Administration (Oral, Intravenous, Subcutaneous), End Users (Hospitals, Diagnostic Laboratories, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Amgen, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Teva Pharmaceutical Industries Ltd (Israel), Fresenius Medical Care AG & Co. KGaA (Germany), Kissei Pharmaceutical Co., Ltd. (Japan), AbbVie Inc. (U.S.), Merck KGaA (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), AstraZeneca (U.K.), Johnson & Johnson Services, Inc. (U.S.), Akebia Therapeutics, Inc. (U.S.), FibroGen, Inc. (U.S.), and Siemens Healthcare GmbH (Germany)
|
|
Market Opportunities
|
|
Market Definition
Chronic Kidney Disease (CKD) is also termed chronic kidney failure characterized by gradual loss of kidney function. There are various types of medications available in the market. Medicines cannot reverse chronic kidney disease, but they treat complications and slow further kidney damage.
Chronic Kidney Disease (CKD) Market Dynamics
Drivers
- Increasing prevalence of CKD
The global prevalence of CKD is rising due to aging populations, sedentary lifestyles, unhealthy diets, and a higher prevalence of risk factors such as diabetes and hypertension. The growing number of CKD cases drives the demand for treatments and management solutions.
- Technological advancements in kidney disease management
Advances in medical technology have led to the development of innovative diagnostic tools, therapeutic options, and treatment modalities for CKD. These advancements include improved screening techniques, biomarkers for early detection, wearable devices for continuous monitoring, and telemedicine platforms for remote patient management.
- Growing awareness and screening initiatives
Increased awareness about kidney health and the importance of early detection has resulted in more people seeking screening for CKD. Public health campaigns, educational programs, and initiatives by healthcare organizations have contributed to the early identification of CKD cases, leading to timely intervention and treatment.
- Rising healthcare expenditure
Governments and private entities are allocating more resources to healthcare, including kidney disease management. Increased healthcare expenditure allows better access to diagnostics, treatment options, and specialized care for CKD patients, thereby driving the market growth.
Opportunities
- Precision medicine approaches
CKD is a heterogeneous condition with various underlying causes and disease trajectories. The application of precision medicine, including genetic profiling, molecular diagnostics, and tailored treatment approaches, can optimize therapeutic outcomes and improve patient care.
-
Digital health and remote monitoring
Integrating digital health technologies, such as wearable devices, remote monitoring systems, and telemedicine platforms, provides opportunities to enhance patient engagement, improve self-management, and enable remote care delivery for CKD patients. These technologies can facilitate real-time monitoring of vital signs, medication adherence, and lifestyle factors, leading to better disease management and reduced hospitalizations.
Restraints/Challenges
- Adverse effects and safety concerns
Some existing treatments for CKD, such as certain medications, can have side effects and safety concerns. Nephrotoxicity, drug interactions, and adverse reactions can limit the use of certain medications or require careful monitoring. Balancing the benefits and risks of treatments is a challenge in CKD management.
-
Limited awareness and early detection
Despite efforts to raise awareness, many cases of CKD remain undiagnosed until the disease has progressed to advanced stages. Late detection hampers the effectiveness of interventions and limits the opportunities for early preventive measures. Increasing awareness, promoting regular screenings, and improving diagnostic methods are essential to address this restraint.
This chronic kidney disease (CKD) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chronic kidney disease (CKD) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In July 2021, Bayer’s KERENDIA (finerenone) received U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
- In April 2021, AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.
Global Chronic Kidney Disease (CKD) Market Scope
The chronic kidney disease (CKD) market is segmented on the basis of product type, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product type
- Diagnosis
- Treatment
Route of administration
- Oral
- Intravenous
- Subcutaneous
End User
- Hospitals
- Diagnostic Laboratories
- Homecare
- Specialty Clinics
- Others)
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Chronic Kidney Disease (CKD) Market Regional Analysis/Insights
The chronic kidney disease (CKD) market is analysed and market size insights and trends are provided by country, product type, route of administration, end user, and distribution channel, as referenced above.
The countries covered in the chronic kidney disease (CKD) market report are U.S., Canada and Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the chronic kidney disease (CKD) market because of the rising prevalence of CKD in the region. Growing investment in healthcare infrastructure is also boosting the market's growth.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The chronic kidney disease (CKD) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for chronic kidney disease (CKD) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the chronic kidney disease (CKD) market. The data is available for historic period 2015-2020.
Competitive Landscape and Chronic Kidney Disease (CKD) Market Share Analysis
The chronic kidney disease (CKD) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the Chronic Kidney Disease (CKD) market are:
- Pfizer Inc. (U.S.)
- Amgen, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Abbott (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GlaxoSmithKline Plc (U.K.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Teva Pharmaceutical Industries Ltd (Israel)
- Fresenius Medical Care AG & Co. KGaA (Germany)
- Kissei Pharmaceutical Co., Ltd. (Japan)
- AbbVie Inc. (U.S.)
- Merck KGaA (U.S.)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- AstraZeneca (U.K.)
- Johnson & Johnson Services, Inc. (U.S.)
- Akebia Therapeutics, Inc. (U.S.)
- FibroGen, Inc. (U.S.)
- Siemens Healthcare GmbH (Germany)
SKU-